CLINICAL_TRIALS
trial_result
· 2021-02-21
Clinical Trial Update: An Efficacy and Safety Study of XP19986 in Subjects With Symptomatic GERD [Phase 2]
Summary
Phase 2 trial updating the efficacy and safety of XP19986 in symptomatic gastroesophageal reflux disease.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: XenoPort, Inc. | Conditions: Gastroesophageal Reflux | Phase 2 | Status: COMPLETED